Death during study period · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in all‐cause mortality (prophylactic trials) (over duration of trial) compared with control/placebo (low certainty).
2 findings from 1 review
Safety of MSC infusion · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
1 finding from 1 review
Health‐related quality of life · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse of malignant disease (prophylactic trials) (>12‐month · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in relapse of malignant disease (prophylactic trials) (>12‐month compared with control/placebo (low certainty).
1 finding from 1 review
Incidence of acute GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs showed no clear difference in incidence of acute GvHD (prophylactic trials) compared with control/placebo (low certainty).
1 finding from 1 review
Incidence of chronic GvHD (prophylactic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
MSCs may leads to lower incidence of chronic GvHD (prophylactic trials) compared with control/placebo (low certainty).
1 finding from 1 review
Acute GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
It is very uncertain whether MSCs changes acute GvHD complete response (therapeutic trials) compared with control/placebo (very low certainty).
1 finding from 1 review
Chronic GvHD complete response (therapeutic trials) · patients with a haematological condition who receive a haematopoietic stem cell transplant as treatment for their condition.
It is very uncertain whether MSCs changes chronic GvHD complete response (therapeutic trials) compared with control/placebo (very low certainty).
1 finding from 1 review
Reduction in rest pain: rest pain score · people with critical limb ischaemia
1 finding from 1 review
Improvement in lower limb perfusion: ABI · people with critical limb ischaemia
1 finding from 1 review
Improvement in lower limb perfusion: TcO₂ reading in mmHg · people with critical limb ischaemia
1 finding from 1 review
All‐cause mortality during hospital stay · people with critical limb ischaemia
1 finding from 1 review
Rate of amputation · people with critical limb ischaemia
1 finding from 1 review
Wound/ulcer healing: number of participants with healing ulcer · people with critical limb ischaemia
BM‐MNCs probably leads to higher wound/ulcer healing: number of participants with healing ulcers compared with BM‐MSCs (moderate certainty).
1 finding from 1 review